Chennai: The board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, has approved financial results for the quarter ended 31 March, 2020.
Commenting on the company’s performance, Shyam S Bhartia, chairman and Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences said: “We are glad to report record profits in FY20 with improvement in margins across all the business segments. The Q4FY20 performance was impressive with EBITDA growth of 58 per cent YoY. Despite the Covid-19 led challenges, we continue to experience strong demand across most of our businesses.”
According to a press note, the company’s FY20 revenue stood at Rs 9,154 crore; Q4 revenue at Rs 2,391 crore.